Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you`re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy. Cookie settings

TAG overview

Results

(9) Net sales

Operating Activities

(9) Net sales

Accounting and measurement policies

Nature and timing of revenue recognition

Net sales are recognized when (or as) the customer obtains control of the asset. For sales of goods, the customer typically obtains control as soon as delivery is made, given that the customer is generally not able to obtain any benefits from the asset before that point in time. To a lesser extent, the Group generates net sales from the sale of goods based on bill-and-hold arrangements. In these cases, net sales are recognized before the goods are delivered to the customer, as soon as the Group has invoiced the products and the additional criteria laid out in IFRS 15.B81 are fulfilled. In the case of equipment sales, the criteria for revenue recognition are only met after installation has been successfully completed – to the extent that the installation requires specialized knowledge, does not represent a clear ancillary service and the relevant equipment can only be used by the customer once successfully set up.

For service contracts, and customer-specific contract manufacturing of goods and equipment, the Group recognizes revenue over time based on the progress towards complete satisfaction of the performance obligation, if there is a contractual claim for payment against the customer for the services already performed. Input- and output-oriented methods are used to appropriately determine progress on a contract-specific basis. Specifically, this is largely performed on the basis of the costs incurred, the time elapsed, or the milestones achieved as of the reporting date.

Intellectual property is out-licensed to a limited extent in the Healthcare and Life Science business sectors. In the Healthcare business sector, these transactions do not usually form part of ordinary activities, meaning that the corresponding income is reported in other operating income (see Note (7) “Collaboration agreements” and Note (13) “Other operating income”).

Net sales from contracts comprising several separate performance obligations are recognized when the respective performance obligation has been fulfilled. This affects, in particular, the sale of goods in combination with services. Multiple-element arrangements of this nature exist to a limited extent in the Applied Solutions business unit in the Life Science business sector and in the Semiconductor Solutions business unit in the Performance Materials business sector.

Determining the transaction price

The Group grants customers various kinds of rebates and discounts. These, as well as anticipated customer refund claims, state compulsory charges, and rebates from health plans and programs are deducted from sales. The most significant portion of these deductions from sales is attributable to the Healthcare business sector.

Sales deductions provided on the invoice as price-reducing items, which will likely be applied by customers when making the respective payments, are recognized as reduction of trade accounts receivable. Expected refunds, such as bonus payments, reimbursements for rights of return, or rebates from health plans and programs, are recognized in the separate item “refund liabilities” on the consolidated balance sheet.

The measurement of sales deductions and refund liabilities resulting from expected rebates and discounts considers the following:

  • past experience,
  • pricing information, and
  • expected sales volume growth rates.

The measurement of sales deductions and refund liabilities resulting from rights of return takes into account historical rates of return for individual product groups, information from distributors on inventory levels, and publicly available information on product sales from sector-specific service providers (in the Healthcare business sector).

Contractual payment terms

Given that the Group generates the large majority of its sales through transactions with simple structures, the company usually has an enforceable right to payment after the performance obligation has been fulfilled. The payment targets contractually agreed between Group and its customers usually range between 30 and 60 days. For some service contracts, the company receives the contractually agreed consideration before the service is delivered; in such cases, the consideration received is presented as a contract liability on the consolidated balance sheet until the revenue has been recognized.

Practical expedients

The Group uses the practical expedient of IFRS 15 in which the promised amount of consideration is not adjusted for the effects of a significant financing component if the period between the fulfillment of a performance obligation and the payment by the customer only amounts to up to one year.

Significant discretionary decisions and sources of estimation uncertainty

Sales deductions

The measurement of sales deductions and the corresponding refund liabilities requires extensive estimates. Uncertainties exist in particular concerning the extent to which past experience serves as a reliable basis for estimating the future development of expected refunds, such as bonus payments, reimbursements for rights of return, or rebates from health plans. External information from distributors and industry services outside of the Group’s control, which are also subject to uncertainty, are used to determine sales deductions.

Due to a lack of past experience, the estimate uncertainty referenced above is particularly relevant for product launches in the Healthcare business sector.

Any changes in estimates of the parameters listed above have a cumulative impact on the net sales recognized in the respective adjustment period.

If the carrying amount of refund liabilities had been 10% higher as of the reporting date, this would have resulted in a € 67 million (2019: € 57 million) reduction in profit before tax.

The following tables present a breakdown of net sales by key product lines/products:

Healthcare

€ million

 

2020

 

2019

Oncology

 

1,116

 

17%

 

1,030

 

15%

thereof: Erbitux®

 

891

 

13%

 

871

 

13%

thereof: Bavencio®

 

156

 

2%

 

103

 

2%

Neurology & Immunology

 

1,662

 

25%

 

1,594

 

24%

thereof: Rebif®

 

1,131

 

17%

 

1,273

 

19%

thereof: Mavenclad®

 

531

 

8%

 

321

 

5%

Fertility

 

1,079

 

16%

 

1,247

 

19%

thereof: Gonal-f®

 

630

 

9%

 

743

 

11%

General Medicine & Endocrinology

 

2,585

 

39%

 

2,557

 

38%

thereof: Glucophage®

 

903

 

14%

 

877

 

13%

thereof: Concor®

 

529

 

8%

 

530

 

8%

thereof: Euthyrox®

 

455

 

7%

 

402

 

6%

thereof: Saizen®

 

234

 

4%

 

238

 

4%

Other

 

197

 

3%

 

287

 

4%

Total

 

6,639

 

100%

 

6,714

 

100%

Life Science

€ million

 

2020

 

20191

Process Solutions

 

3,596

 

48%

 

3,002

 

44%

Research Solutions

 

2,215

 

29%

 

2,170

 

31%

Applied Solutions

 

1,704

 

23%

 

1,692

 

25%

Total

 

7,515

 

100%

 

6,864

 

100%

1

Previous year’s figures have been adjusted due to an internal realignment.

Performance Materials

€ million

 

2020

 

20191

Semiconductor Solutions

 

1,901

 

56%

 

878

 

34%

Display Solutions

 

1,108

 

33%

 

1,256

 

49%

Surface Solutions

 

370

 

11%

 

438

 

17%

Other

 

1

 

 

2

 

Total

 

3,380

 

100%

 

2,574

 

100%

1

Previous year’s figures have been adjusted due to an internal realignment.

The following tables present a more detailed breakdown of net sales by business sector from contracts with customers.

2020

€ million

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by product type

 

Healthcare

 

Life Science

 

Performance Materials

 

Group

Goods

 

6,496

 

98%

 

6,585

 

88%

 

3,029

 

90%

 

16,111

 

92%

Equipment

 

5

 

 

386

 

5%

 

254

 

7%

 

645

 

4%

Services

 

56

 

1%

 

535

 

7%

 

96

 

3%

 

686

 

4%

License income

 

 

 

9

 

 

1

 

 

10

 

Commission income

 

18

 

 

 

 

 

 

18

 

Income from co-commercialization agreements

 

65

 

1%

 

 

 

 

 

65

 

Total

 

6,639

 

100%

 

7,515

 

100%

 

3,380

 

100%

 

17,534

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by region (customer location)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

 

2,158

 

32%

 

2,583

 

35%

 

250

 

8%

 

4,991

 

29%

North America

 

1,554

 

23%

 

2,701

 

36%

 

484

 

14%

 

4,739

 

27%

Asia-Pacific

 

1,831

 

28%

 

1,900

 

25%

 

2,582

 

76%

 

6,313

 

36%

Latin America

 

641

 

10%

 

241

 

3%

 

28

 

1%

 

910

 

5%

Middle East and Africa

 

455

 

7%

 

89

 

1%

 

37

 

1%

 

581

 

3%

Total

 

6,639

 

100%

 

7,515

 

100%

 

3,380

 

100%

 

17,534

 

100%

2019

€ million

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by product type

 

Healthcare

 

Life Science

 

Performance Materials

 

Group

Goods

 

6,531

 

97%

 

5,972

 

87%

 

2,497

 

97%

 

15,000

 

93%

Equipment

 

7

 

 

397

 

6%

 

50

 

2%

 

454

 

3%

Services

 

100

 

2%

 

486

 

7%

 

25

 

1%

 

611

 

4%

License income

 

 

 

8

 

 

 

 

8

 

Commission income

 

18

 

 

2

 

 

1

 

 

21

 

Income from co-commercialization agreements

 

58

 

1%

 

 

 

 

 

58

 

Total

 

6,714

 

100%

 

6,864

 

100%

 

2,574

 

100%

 

16,152

 

100%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales by region (customer location)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Europe

 

2,241

 

33%

 

2,277

 

33%

 

217

 

9%

 

4,735

 

29%

North America

 

1,474

 

22%

 

2,474

 

36%

 

267

 

10%

 

4,214

 

26%

Asia-Pacific

 

1,816

 

27%

 

1,743

 

26%

 

2,041

 

79%

 

5,599

 

35%

Latin America

 

702

 

11%

 

278

 

4%

 

32

 

1%

 

1,012

 

6%

Middle East and Africa

 

482

 

7%

 

92

 

1%

 

17

 

1%

 

591

 

4%

Total

 

6,714

 

100%

 

6,864

 

100%

 

2,574

 

100%

 

16,152

 

100%

Group net sales amounted to € 17,534 million in fiscal 2020 (2019: € 16,152 million), out of which € 697 million (2019: € 683 million) was recognized over time. This related mainly to net sales from services and from customer-specific equipment in the Applied Solutions and Process Solutions business units in the Life Science business sector and in the Semiconductor Solutions business unit in the Performance Materials business sector.

The table below shows future net sales from concluded contracts:

 

 

Year of expected revenue recognition

€ million

 

2021

 

2022 or later fiscal years

 

Total

As of Dec. 31, 2020

 

3,892

 

376

 

4,268

 

 

Year of expected revenue recognition

€ million

 

2020

 

2021 or later fiscal years

 

Total

As of Dec. 31, 2019

 

2,018

 

145

 

2,163

The significant increase compared with the previous year resulted, in particular, from the positive performance of the Process Solutions business unit in the Life Science business sector.

The following table shows the change in refund liabilities:

2020

 

 

Rebates/Bonus payments

 

Rights of return

 

 

€ million

 

Total

 

thereof: United States

 

Total

 

thereof: United States

 

Total

Jan. 1, 2020

 

522

 

315

 

43

 

29

 

565

Additions due to business combinations

 

 

 

 

 

Other additions

 

1,713

 

1,234

 

41

 

20

 

1,754

Disposals due to divestments/
Reclassification to assets held for sale

 

-8

 

 

 

 

-8

Utilizations

 

-1,501

 

-1,081

 

-33

 

-17

 

-1,534

Cumulative increase (-)/decrease (+) in net sales

 

-66

 

-67

 

-3

 

-4

 

-69

thereof: attributable to performance obligations satisfied in prior periods

 

-48

 

-48

 

-3

 

-3

 

-51

Currency translation difference

 

-39

 

-35

 

-4

 

-3

 

-42

Other

 

1

 

 

 

 

1

Dec. 31, 2020

 

622

 

368

 

44

 

26

 

666

2019

 

 

Rebates/Bonus payments

 

Rights of return

 

 

€ million

 

Total

 

thereof: United States

 

Total

 

thereof: United States

 

Total

Jan. 1, 2019

 

423

 

274

 

49

 

31

 

472

Additions due to business combinations

 

 

 

 

 

Other additions

 

1,488

 

1,145

 

36

 

23

 

1,524

Disposals due to divestments/
Reclassification to assets held for sale

 

 

 

 

 

Utilizations

 

-1,344

 

-1,067

 

-41

 

-25

 

-1,385

Cumulative increase (-)/decrease (+) in net sales

 

-44

 

-43

 

-2

 

 

-46

thereof: attributable to performance obligations satisfied in prior periods

 

-43

 

-43

 

-2

 

 

-45

Currency translation difference

 

8

 

6

 

1

 

1

 

9

Other

 

-9

 

 

 

 

-9

Dec. 31, 2019

 

522

 

315

 

43

 

29

 

565

The development of contract assets and contract liabilities is shown in Note (26) “Contract assets” and in Note (29) “Other non-financial liabilities”.